With the incomparable Mempro™ virus-like particles (VLPs) platform established for a long time, Creative Biostructure has developed various methods for appropriate post-translational modification of VLPs. Scientists from Creative Biostructure can perform Mempro™ VLPs amino acid attachment modification services.
VLPs are composed of structural proteins of viruses and they are non-infectious protein structures which can self-assemble into either icosahedral or rod-like structures. VLPs can induce strong antibody responses duo to the repeated surface epitopes on them, and they are ideal for trafficking to the lymphatic system to cause T-cell responses, for they have a proper size, representatively 25-100 nm. Therefore, the immunogenic properties of VLPs have led them to a fascinating target as the core of effective vaccines. Creative Biostructure can attach foreign epitopes to VLPs based on the Mempro™ VLPs amino acid attachment modification platform.
Figure 1. Covalently linking a polypeptide to a VLP by chemical coupling. (Biol. Chem 2008)
All kinds of molecules have been merged into VLPs, including polypeptides, proteins, capsular polysaccharides and small organic molecules (haptens). There are two methods for target epitopes combine with VLPs, one is genetically fusing into subunit proteins of the VLPs to form chimeras, the other is attaching to the surface of the VLPs by covalent or non-covalent means. VLPs not only can serve as carriers of immunologic epitopes that are obtained from microbial pathogens, but also they have been triumphantly used to overcome B-cell unresponsiveness and display self-antigens to the immune system.
The capacity of VLPs to act as carriers of B-cell epitopes arose from either the parental virus or foreign sources has highly enhanced and enlarged their potential as prophylactic and therapeutic vaccines. The low immune response of a lot of soluble antigens enable to be conquered by rendering them extremely repetitive. This can be accomplished by combining them onto or into the surface of VLPs. By this means, the potential immunogenic ‘viral fingerprint’ of the VLP is afforded to the attached epitope making it as effective an immunogen as the VLP itself.
Creative Biostructure has been pioneered in the VLPs production for a long time, we can provide various Mempro™ VLPs modification strategies services. Please feel free to contact us for a detailed quote.
Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses[J]. Vaccine, 2002, 20(25): 3104-3112.
Jennings G T, Bachmann M F. The coming of age of virus-like particle vaccines[J]. Biological chemistry, 2008, 389(5): 521-536.
Ambühl P M, Tissot A C, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity[J]. Journal of hypertension, 2007, 25(1): 63-72.